Kornimate/medical-research-clean huggingface dataset:
electronic self-management resource training for mental health

Conditions: Depression; Generalized Anxiety Disorder

Summary: the purpose of this study is to determine whether mental health treatment disengagement may be mitigated by reducing barriers to self-management and enhancing self-management skills.

each year, more than four million young adults (age 18-25 years old) in the u.s. receive psychotropic medication or psychotherapy as treatment for a mental illness. one in every four of these young adults will disengage from mental health treatment before significant symptom remission is achieved. mental health treatment disengagement may be mitigated by reducing barriers to self-management and enhancing self-management skills. electronic self-management resource training for mental health (esmart-mh) is an innovative use of avatars-virtual persons who tailor responses to users-to improve mental health treatment disengagement.

Eligibility criteria:
inclusion criteria: * self-report of a diagnosis depression or generalized anxiety disorder greater than six months * young adults 18-25 years of age * prescribed psychotropic medication and/or psychotherapy * have a documented domestic telephone number * able to read and understand english exclusion criteria: * participation in the esmart-hd parent project
switch to dovato in patients suppressed on biktarvy (sound)

Conditions: Human Immunodeficiency Virus

Summary: an open-label, pilot study of switching patients to dovato who are currently taking bitarvy who are virological suppressed (hiv-1 \< 50 copies/ml


Eligibility criteria:
inclusion criteria: 1. confirmed hiv-1 infection 2. age of 18 years or older 3. on biktarvy for at \>24 weeks with hiv viral load \ 6 months immediately prior to enrollment 4. agree to consistently use an effective method of contraception (see appendix: highly effective methods for avoiding pregnancies in females of reproductive potential) for women of child-bearing potential 5. willingness to sign the informed consent 6. if history of virologic failure must be fully suppressed (hiv-1 rna\<50 copies/ml) for at least 12 months before screening visit 7. no prior hiv genotype or phenotype available exclusion criteria: 1. hypersensitivity to dolutegravir and/or lamivudine 2. history of virologic failure while on an integrase inhibitor 3. taking any medication contraindicated for co-administration with dolutegravir and/or lamivudine according to manufacturer's current medication package inserts 4. hiv-1 rna ≥50 copies/ml (confirmed) in the past 48 weeks after initial suppression on therapy to hiv-1 rna \<50 copies/ml 5. evidence of hepatitis b virus (hbv) infection based on the results of testing at screening for hepatitis b surface antigen (hbsag), hepatitis b core antibody (anti-hbc), hepatitis b surface antigen antibody (anti-hbs) and hbv dna as follows: * participants positive for hbsag are excluded. * participants negative for anti-hbs but positive for anti-hbc (negative hbsag status) and positive for hbv dna are excluded. note: participants positive for anti-hbc (negative hbsag status) and positive for anti-hbs (past and/or current evidence) are immune to hbv and are not excluded. anti-hbc must be either total anti-hbc or anti-hbc immunoglobulin g (igg), and not anti-hbc igm. participants with a documented history of chronic hbv and current undetectable hbv dna while on a biktarvy are excluded. 6. pregnant women, women actively seeking to become pregnant, and women of child-bearing potential who are not using effective contraception 7. severe hepatic impairment (child-pugh c) 8. critically ill and/or unable to take oral medications 9. any condition (social or medical) which, in the opinion of the investigator, would make study participation unsafe for the subject 10. creatinine clearance \< 30 ml/min/1.73m2 via ckd-epi method 11. alt \> 5x the upper limit of normal (uln) or alt \> 3x uln and total bilbirubin \>1.5x uln (and \>35% directed bilirubin) 12. subjects with an anticipated need for hepatitis c virus therapy with interferon and/or ribavirin prior to the primary endpoint 13. unstable liver disease, cirrhosis, and/or known biliary abnormalities (except for hyperbilirubinemia or jaundice due to gilbert's syndrome or asymptomatic gallstones)
sto2 performance measured on admission to the emergency department in the assessment of drug poisoning

Conditions: Drug Poisoning

Summary: the primary purpose of the protocol is to evaluate the sto2 performance measured at the admission to the emergency department to identify hemodynamic failure at the admission or within the first three hours of monitoring patients with drug poisoning. the study hypotheses are: * the early detection of hypoperfusion by sto2, essential to prevent the development of collapse. * to limit hemodynamic failure effects, reduce morbidity and mortality of drug poisoning, hospital stay and cost.

the procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. the system used in the study is the tissue oxygenation monitor inspectratm sto2 spot check, model 300 consisting of a clamp applied to the base of the thumb of the patient.

Eligibility criteria:
inclusion criteria: * admitted to the emergency department, * whose pattern of hospitalization is drug poisoning, defined on data from the patient's interrogation or his family if the patient is not able to answer, * written informed consent signed by the patient or, if he's unable to sign, by a companion, * affiliated to medical insurance exclusion criteria: * patients without thenar eminence or having a disease of the thenar, * refusal to participate in the study, * participation in another biomedical research, * patient under guardianship, trusteeship or judicial protection, * pregnant women or nursing mothers

Keywords: emergency drug poisoning sto2 measurement blood pressure hemodynamic failure
the healthcare professionals and the leishmaniasis

Conditions: Knowledge on Leishmaniasis

Summary: the aim of this work was to investigate the healthcare professionals' knowledge about leishmaniasis in divinópolis, an endemic county of minas gerais state, brazil.


Eligibility criteria:
inclusion criteria: * work in the healthcare centers, in the case of primary care professionals; * have a university degree for nurses, physicians, dentists and veterinarians; * be working effectively at the time of the interview; * accept the terms of the research through written informed consent. exclusion criteria: -
rt or no rt following chemotherapy in treating patients with stage iii/iv hodgkin's disease

Conditions: Lymphoma

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining radiation therapy with combination chemotherapy may kill more tumor cells. purpose: randomized phase iii trial to compare the effectiveness of radiation therapy with no radiation therapy following chemotherapy in treating patients with stage iii or stage iv hodgkin's disease.

objectives: i. compare relapse-free survival and overall survival of patients with stage iii/iv hodgkin's disease randomly assigned to adjuvant involved-field radiotherapy vs. no adjuvant therapy following remission induction with mopp/abv (nitrogen mustard/vincristine/procarbazine/prednisone/doxorubicin/bleomycin/vinblastine). ii. evaluate the therapeutic efficacy of mopp/abv hybrid chemotherapy in advanced hodgkin's disease. iii. evaluate the prognostic significance of an early response to mopp/abv in patients with advanced hodgkin's disease. outline: study randomized for adjuvant radiotherapy. all patients receive induction chemotherapy on regimen a, following which those in cr are randomized on arms i and ii. regimen a: 7-drug combination chemotherapy. mopp/abv hybrid. mechlorethamine, nm, nsc-762; vincristine, vcr, nsc-67574; procarbazine, pcb, nsc-77213; prednisone, pred, nsc-10023; doxorubicin, dox, nsc-123127; bleomycin, bleo, nsc-125066; vinblastine, vbl, nsc-49842. arm i: radiotherapy. involved-field irradiation using megavoltage equipment. arm ii: no further therapy. projected accrual: 321 evaluable patients will be required; an annual accrual rate of 80 patients is anticipated.

Eligibility criteria:
disease characteristics: histologically proven clinical or pathological stage iii/iv hodgkin's disease pathological stage iiias disease with the spleen as the only site of subdiaphragmatic involvement excluded patient characteristics: age: 15 to 70 performance status: not specified life expectancy: no severe limits on life expectancy due to nonmalignant disease hematopoietic: not specified hepatic: not specified renal: not specified cardiovascular: no severe cardiac disease that would preclude protocol therapy pulmonary: no severe pulmonary disease that would preclude protocol therapy other: no severe metabolic or neurologic disease that would preclude protocol therapy no concomitant or previous second malignancy except: nonmelanomatous skin cancer in situ carcinoma of the cervix prior concurrent therapy: no prior therapy

Keywords: stage iii adult hodgkin lymphoma stage iv adult hodgkin lymphoma
efficacy and safety of baricitinib in neuromyelitis optica spectrum disorders

Conditions: NMO Spectrum Disorder

Summary: neuromyelitis optica spectrum disorders (nmosd) is associated with a pathological humoral immune response against the aquaporin-4(aqp-4) water channel. baricitinib is an oral janus kinase (jak)1/jak2 inhibitor that blocks the upregulated jak-stat pathway in patients with neuroimmune disorders, which is important in bone marrow regulation of b cell proliferation and differentiation. baricitinib may benefit some patients with nmosd due to the important role of b cells in the pathogenesis of nmosd. clinical trials may be needed to observe its efficacy and safety.

the investigators primarily aim to observe the number of attacks from initiation of baricitinib treatment. the secondary outcomes are to determine: the safety profile of baricitinib in participants with nmo and whether baricitinib improves expanded disability status scale (edss), et al.

Eligibility criteria:
inclusion criteria: 1. male or female patients ≥ 18 years old; 2. diagnosis of nmo or nmo spectrum disorder according to the 2015 international panel for neuromyelitis optica diagnosis criteria; 3. clinical evidence of either at least one attack requiring rescue therapy (intravenous corticosteroids, intravenous immunoglobulin, plasma exchange, or a combination of these therapies) in the year before screening or at least two attacks requiring rescue therapy in the 2 years before screening; 4. edss \<=6.0; 5. patients were seropositive for aqp4-igg; 6. able and willing to give written informed consent and comply with the requirements of the study protocol. exclusion criteria: 1. current evidence or known history of clinically significant infection (herpes simplex virus, varicella-zoster virus, cytomegalovirus, epstein-barr virus, human immunodeficiency virus, hepatitis viruses, syphilis, etc); 2. participation in another interventional trial within the last 3 months tumor disease currently or within last 5 years; 3. pregnant, breastfeeding, or child-bearing potential during the course of the study clinically relevant heart, liver, kidney or bone marrow function disorder. 4. have a history of venous thromboembolism (vte), or are considered at high risk for vte by the investigator.
healaflow patch for the treatment of rhegmatogenous retinal detachment

Conditions: Rhegmatogenous Retinal Detachment

Summary: to report the surgical results of primary rhegmatogenous retinal detachment (rrd) repaired by 27g pars plana vitrectomy (ppv) combined with healaflow patch and air tamponade, and do not need prone position postoperation.

to improve the success rates of pars plana vitrectomy(ppv) which is the most common surgical procedure for the repair of primary rhegmatogenous retinal detachment (rrd) and to avoid silicon oil tamponade and face-down position, all eyes enrolled into this clinical trail undergo 27g ppv combined with healaflow patch and air tamponade which do not need face-down position in the postoperative period. healaflow® (anteis s.a., plan les ouates, switzerland) consists of over 97% water, sodium hyaluronic acid (22.5 mg/ml) of nonanimal origin cross-linked with bdde (1.4-butanediol diglycidyl ether), and phosphate- and nacl-salts to maintain a physiological ph (7.0) and osmolarity (305 mosm/kg). at the time of study enrollment, physical examinations, best-corrected visual acuity (bcva), intraocular pressure(iop) will be measured and fundoscopy, oct, b-ultrasound will be performed. the patients are going to be followed up for at least 3 months, the main outcome measures are postoperative primary and final anatomic outcome, bcva and complications.

Eligibility criteria:
inclusion criteria: - patients with primary rrd exclusion criteria: - proliferative vitreoretinopathy grade c or more, dialysis, retinoschisis, eyes with secondary rrd, significant corneal or lens opacity precluding vitrectomy, giant retinal tears, a follow-up period of less than 3 months, and visual loss from causes other than rrd

Keywords: healaflow rhegmatogenous retinal detachment 27-gauge pars plana vitrectomy minimally invasive surgery complications
pct of pharmacopuncture for chronic neck pain

Conditions: Neck Pain; Chronic Pain

Summary: a pragmatic clinical study to compare the effectiveness of pharmacopuncture and acupuncture treatment strategies in patients with chronic neck pain

this study aims to confirm the comparative effectiveness of pharmacopuncture by conducting a pragmatic randomized controlled clinical trial with 128 patients suffering from chronic neck pain. the trial will compare patients treated with a pharmacopuncture-based strategy (64 patients) to those treated with an acupuncture-based strategy (64 patients). as this is a pragmatic clinical trial, participants will be randomly assigned to either the pharmacopuncture or acupuncture groups. however, the specific methods of pharmacopuncture and acupuncture to be used will not be predetermined. instead, they will be determined based on the clinical judgment of the traditional korean medicine doctor according to the patient's condition. all methods used will be recorded in the crf (case report form).

Eligibility criteria:
inclusion criteria: 1. patients with neck pain persisting for more than 3 months 2. patients with a numeric rating scale (nrs) score of 5 or higher for neck pain 3. patients aged between 19 and 70 years 4. patients who agree to participate in the clinical study and provide a written informed consent form exclusion criteria: 1. patients diagnosed with serious specific diseases that could be the cause of neck pain (e.g., spinal metastasis of tumors, acute fractures, and spinal dislocations) 2. patients exhibiting progressive neurological deficits or severe neurological symptoms 3. patients whose pain originates from soft tissue disorders rather than the spine (e.g., tumors, fibromyalgia, rheumatoid arthritis, gout) 4. patients with other chronic diseases that could interfere with the interpretation of treatment effects or outcomes (e.g., stroke, myocardial infarction, kidney disease, diabetic neuropathy, dementia, epilepsy) 5. patients currently taking steroids, immunosuppressants, psychiatric medications, or other drugs that could affect the study results 6. patients for whom pharmacopuncture treatment is inappropriate or unsafe: those with bleeding disorders, those undergoing anticoagulant therapy, and severe diabetic patients with infection risks 7. patients who have taken medications that could affect pain (e.g., non-steroidal anti-inflammatory drugs, nsaids) or received pharmacopuncture, acupuncture, or physical therapy within the past week 8. pregnant women, those planning to become pregnant, or those currently breastfeeding 9. patients who have undergone cervical spine surgery within the past 3 months 10. patients who have not completed participation in another clinical study within the past month or plan to participate in another clinical study during the study participation and follow-up period within 6 months from the date of selection 11. patients who find it difficult to provide informed consent for participation 12. other cases where the researcher deems participation in the clinical study to be difficult
insulin glargine, initiate metabolic and economic outcomes of lantus

Conditions: Diabetes Mellitus

Summary: to introduce initiation of glargine insulin treatment in primary care based on a patient education program. to show and compare feasibility of group education to individual education program.


Eligibility criteria:
inclusion criteria: * insulin-naive type 2 diabetes mellitus subjects, aged ≥18 years and on stable oral anti-diabetic treatment for \>6 months requiring basal long-acting insulin (hba1c \>7.5 % and \<12.0 %). exclusion criteria: * the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
bioequivalency study of protriptyline 10 mg tablets under fasted conditions

Conditions: Depression

Summary: the objective of this study was to prove the bioequivalence of protriptyline 10 mg tablets under fasted conditions


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening exclusion criteria: * positive test for hiv, hepatitis b, or hepatitis c. * treatment with known enzyme altering drugs. * history of allergic or adverse response to protriptyline or any comparable or similar product.
canrenone effects on cardiovascular mortality in patients with congestive heart failure (the coffee-it study)

Conditions: Cardiac Heart Failure Patients

Summary: to evaluate canrenone effects compared to other therapies on cardiovascular mortality in patients with congestive heart failure and preserved systolic function after 12 years of evaluation.

the investigators will verify patients with cardiac heart failure (chf) and preserved systolic function and each patient must have all clinical evaluation through basal measurements of blood pressure, heart rate, biochemical tests, and color doppler echocardiographic parameters for at least 12 years. the investigators will evaluate the effects of an aldosterone antagonist as canrenone compared to a group without canrenone and the investogators will verify how many patients reported cardiovascular mortality or will survive.

Eligibility criteria:
inclusion criteria: * patients with chf * preserved systolic function (fe ≥ 45%) exclusion criteria: * severe hypertension identified by blood pressure ≥180/110 mmhg * patients with impaired systolic function (fe \< 45%) * history of active hepatitis or cirrhosis * impaired renal function * hyperpotassemia * diabetes

Keywords: chf canrenone
analytic and functional evaluation after surgical treatment using an original arthroscopic trillat technique in patients with chronic anterior shoulder instability

Conditions: Chronic Anterior Shoulder Instability

Summary: the shoulder is the most mobile joint in the body, and the most exposed to the risk of dislocation notably anterior. chronic instability of the shoulder is frequent after dislocation, and principally affects people who are young and active. it can have major functional repercussions, leading to restricted participation in professional or sports activities, even in everyday life activities. surgical stabilisation is the reference treatment for chronic anterior shoulder instability, and has given good results. there are numerous surgical techniques available; the orthopaedists at dijon chu now practice the bristow-trillat technique under arthroscopy, following many years of reflexion and adaptation. rehabilitation following the surgery is essential, notably to recover muscle strength in the shoulder rotator cuff after surgery, which correlates directly with dynamic stability of the joint. at the moment, we do not know the objective evolution of muscle strength after the trillat arthroscopic technique. the isokinetic evaluation of muscle strength in the rotator cuff has been validated and is reproducible. it gives objective and reliable values for muscle strength, thus making it possible to guide and to optimise rehabilitation protocols done by patients under the supervision of a physiotherapist, and to estimate time to the return to physical, professional or sports activities, without risk.


Eligibility criteria:
inclusion criteria: * persons informed about the research * male or female * age between 16 and 45 years * regular sport activity (leisure or competition) * first surgical indication for stabilisation using the trillat arthroscopic technique * patient operated on using the trillat arthroscopic technique for chronic anterior shoulder instability in the orthopaedic and trauma unit of dijon chu exclusion criteria: * persons without health insurance cover * concomitant, disabling shoulder joint disease inflammatory rheumatism, which could be exacerbated by the tests * associated lesions in the shoulder: rupture of rotator cuff tendons, neurological lesions, bone lesions: fracture of the neck of humerus, of the greater tubercle or the coracoid process * paraplegia and peripheral neurological disease * surgery other than the trillat arthroscopic technique alone * treatment with the trillat arthroscopic technique as second line, after failure of the first strategy * contralateral history of dislocation with surgical repair * history of disease with excess laxity (collagen disease, marfan, elhers-danlos) * history of debilitating pain in the back, elbows or wrists * contra-indication for isokinetic tests * cognitive disorders * major post-operative complications delaying the rehabilitation * early recurrence of dislocation after surgery * post-operative immobilisation protocol not respected
high-dose periop statins for prevention of dvt

Conditions: Gynecologic Oncological Pelvic/Abdominal Surgery

Summary: this study is designed to determine if the use of atorvastatin (lipitor), a member of the hmg coa reductase inhibitor class of drugs referred to as statins, will reduce inflammatory responses and deep vein thrombosis formation when given in high doses in the perioperative period.


Eligibility criteria:
inclusion criteria: * gynecologic tumor scheduled for resection exclusion criteria: * prior reaction to statins * renal insufficiency * liver disease * h/o alcoholism * prior h/o dvt or hypercoagulability * concurrent medications that significantly affect cytochrome p450 3a4 * breast feeding or pregnancy

Keywords: cancer--ovarian cancer--endometria deep vein thrombosis statin therapy in perioperative period